What is Infinimmune?
Infinimmune operates at the intersection of advanced biotechnology and computational science. By leveraging human immune repertoires, the company specializes in the discovery and optimization of human-derived antibody therapeutics. Their technical stack integrates high-throughput sequencing, sophisticated antibody engineering, and artificial intelligence to address complex autoimmune and inflammatory conditions. This multidisciplinary approach positions Infinimmune as a high-growth entity within the biopharmaceutical sector, capable of translating intricate biological data into scalable, novel biologics for serious disease states.
How much funding has Infinimmune raised?
Infinimmune has raised a total of $75M across 1 funding round:
Series A
$75M
Series A (2026): $75M with participation from Merck Global Health Innovation Fund, Civilization Ventures, Goldcrest Capital, Pear VC, Playground, Regeneron Ventures, and RA Capital Management
Key Investors in Infinimmune
Merck Global Health Innovation Fund
A growth investor that partners with innovative digital health and data science companies to facilitate and optimize biopharmaceutical operations.
Civilization Ventures
A venture capital firm focused on preventative, personalized, and regenerative healthcare solutions with a strong track record in genomics and diagnostics.
Goldcrest Capital
A venture capital fund specializing in private technology companies, providing both capital and strategic guidance to help startups scale their operations.
What's next for Infinimmune?
With this recent capital injection, Infinimmune is well-positioned to accelerate its clinical pipeline and expand its computational discovery capabilities. The strategic backing from industry-leading investors provides not only the necessary liquidity to scale operations but also access to deep domain expertise in drug development and commercialization. Moving forward, the company is expected to prioritize the advancement of its lead candidates through preclinical validation, while simultaneously refining its AI-driven platform to shorten the discovery cycle for future therapeutic assets. This phase of growth will likely focus on strengthening intellectual property portfolios and establishing key partnerships to facilitate the transition from laboratory research to clinical-stage development.
See full Infinimmune company page